Biotech: Page
-
Revance CEO stepping down over 'misjudgment'
Dan Browne, who has led Revance for the past 17 years, will be replaced by board member and former Zeltiq CEO Mark Foley.
By Ned Pagliarulo • Oct. 14, 2019 -
Five Prime's restructuring claims more jobs
Roughly 70 jobs will be eliminated, leaving a "small research group" to develop the California biotech's three wholly-owned drugs.
By Jacob Bell • Oct. 11, 2019 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Gene therapy biotechs caught in manufacturing crunch
Rising demand for contract manufacturing services could push companies to invest more in their own capabilities despite the high cost.
By Ned Pagliarulo • Updated Oct. 11, 2019 -
Reata buys drug rights back from AbbVie for $330M before readout
"It shows our confidence, but we'll have to see how the data plays out," the biotech's CFO told BioPharma Dive.
By Andrew Dunn • Oct. 10, 2019 -
Arbutus stops early hepatitis B study on safety concerns
Shares in the Pennsylvania biotech shed a quarter of their value Friday, putting the company down more than 70% for the year.
By Ned Pagliarulo • Oct. 4, 2019 -
Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion
The FDA approved Descovy to prevent HIV infection in adults and adolescents, but not for cisgender women.
By Jacob Bell • Oct. 4, 2019 -
Gene therapy stocks have taken a beating. Their recovery may be slow
Share prices of at least 26 gene therapy biotechs were down on the year in October, a sign of some investor uncertainty on how the drugs will be sold.
By Jacob Bell • Oct. 3, 2019 -
Tocagen to lay off two-thirds of company after R&D setback
After a brain cancer study missed its goal last month, the San Diego biotech said it will keep only 30 employees in order to extend its cash runway.
By Andrew Dunn • Oct. 3, 2019 -
Amicus rare disease data build hope for approval
The real test of the Pompe disease therapy, however, will be an enrolling Phase 3 study that's set to read out data in 2021.
By Jonathan Gardner • Oct. 2, 2019 -
NewLink's two-decade run ends in reverse merger, layoffs
Following the collapse of the biotech's oncology prospects last year, NewLink will now merge with privately held Lumos Pharma.
By Andrew Dunn • Oct. 1, 2019 -
Biogen's R&D head is out, following string of clinical setbacks
Chief Medical Officer Alfred Sandrock is, effective immediately, taking on the duties of Michael Ehlers, who's set to leave Biogen on Oct. 11.
By Jacob Bell • Oct. 1, 2019 -
Seattle Genetics makes case it can be more than Adcetris
Known best for its approved antibody drug conjugate, the biotech impressed at ESMO with positive results from two experimental drugs.
By Ned Pagliarulo • Sept. 30, 2019 -
Retrieved from National Cancer Institute on September 27, 2019
Colon cancer proves tougher target for Amgen's KRAS drug
A much lower response rate in colorectal cancer than in lung could signal the two tumor types respond differently to blocking KRAS with AMG 510.
By Ned Pagliarulo • Sept. 28, 2019 -
Cancer immunotherapy boom showing no sign of slowdown
A new report from the Cancer Research Institute found nearly 3,900 drugs in preclinical and clinical development, up 91% from just two years ago.
By Ned Pagliarulo • Updated Sept. 27, 2019 -
Investors conclude there are probably better NASH drugs than Enanta's
The biotech's stock plummeted more than 18% Thursday as data showed its FXR agonist barely cleared the threshold for success in a Phase 2 study.
By Jacob Bell • Sept. 26, 2019 -
Medicines Co. gets cholesterol confirmation
The biotech secured positive results from two more Phase 3 trials of inclisiran, clearing a final step before submitting the PCSK9 drug to the FDA.
By Jonathan Gardner • Sept. 25, 2019 -
Clovis shares plunge after downgrade raises questions on path forward
A Wall Street analyst was skeptical of a preclinical deal that adds R&D costs while the company fights for market share in ovarian cancer.
By Jonathan Gardner • Sept. 24, 2019 -
Alder's migraine drug attracted plenty of dealmakers. The company, not so much
A new regulatory filing affirms the theory that, in neuroscience, risk-sharing partnerships are more appealing than all-out acquisitions.
By Jacob Bell • Sept. 24, 2019 -
Amag fights activist investor's bid for board seats
After increasing its stake to 10%, a hedge fund has launched a board bid as Amag works to commercialize a female libido pill.
By Jonathan Gardner • Sept. 23, 2019 -
3 Akcea execs, including CEO, leave in a 'disconcerting surprise'
"It's hard to see this abrupt transition as not being disruptive to the ongoing Tegsedi launch," noted one analyst, referring to the biotech's antisense drug.
By Andrew Dunn • Sept. 23, 2019 -
Focusing on cystic fibrosis, Translate Bio to raise $90M
The fundraising follows Translate's inking of a five-year manufacturing deal with AMRI, aimed at supporting development of its mRNA products.
By Kristin Jensen • Sept. 18, 2019 -
Alexion's CFO steps down in surprise departure
Known for his 'legendary caution,' Paul Clancy will be succeeded by Alexion's head of business development Aradhana Sarin.
By Ned Pagliarulo • Sept. 18, 2019 -
Vertex hits a biomarker bump on road to new drug
Following an FDA workshop, analysts believe Vertex will need to show its drug for AAT deficiency offers some functional benefit rather than just a biomarker effect.
By Jacob Bell • Sept. 17, 2019 -
Acceleron dealt pipeline setback
The biotech's muscular dystrophy drug ACE-083 failed a Phase 2 trial, putting the spotlight for Acceleron more firmly on Celgene-partnered luspatercept.
By Jonathan Gardner • Sept. 17, 2019 -
Lundbeck buys into migraine, acquiring Alder for $2B
The Danish pharma has blockbuster ambitions for Alder's CGRP drug, but the already competitive migraine market is poised to become more so next year.
By Andrew Dunn • Sept. 16, 2019